The Companys lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD)
1st Phorm L-Carnitine with Fucoxanthin provides the most innovative dual-mechanism approach for fat loss
began to take GLP-1 drugs, total spending could reach $411 billion
GLP-1 Receptor Agonists and Sleep Quality in Patients with Type 2 Diabetes. Retrieved November 30, 2025
Entropy 15:14161463 Schrder P (2001) The role of glutathione and glutathione S-transferase in plant reaction and adaptation to xenobiotics
Style Guide: If youre looking to turn heads with a modern, stylish cut, make a fade your new signature look